Shares of Medpace Holdings Inc. (MEDP) plummeted 13.24% in intraday trading on Tuesday, as investors reacted negatively to the clinical research company's conservative full-year guidance and signs of slowing business momentum, despite reporting better-than-expected first-quarter results.
Medpace's Q1 2025 performance exceeded analyst expectations, with revenue of $558.6 million surpassing estimates of $527.2 million and earnings per share (EPS) of $3.67 beating the projected $3.06. However, the company's full-year 2025 outlook fell short of market expectations, projecting EPS between $12.26 and $13.04 and revenue between $2.14 billion and $2.24 billion, representing a modest growth of 1.5% to 6.2% over 2024.
Investors' concerns were further amplified by a reported 18.8% decrease in net new business awards to $500.0 million and a lower book-to-bill ratio of 0.90x, suggesting potential challenges in maintaining the company's growth trajectory. Adding to the negative sentiment, Deutsche Bank cut its price target for Medpace from $325 to $280, while maintaining a Hold rating. The combination of conservative guidance, slowing business momentum, and the analyst downgrade appears to have triggered the significant sell-off, overshadowing the company's strong quarterly performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.